Cellceutix Corp (OTCMKTS:CTIX) is trading higher in recent days and continues to consolidate well. The stock was recently the subject of a short attack led by...
Cellceutix Corp (OTCMKTS:CTIX) continues to consolidate well over the $3.50 range after a recent short attack led by 2 misleading Seeking Alpha articles momentarily dropped the...
Cellceutix Corp (OTCMKTS:CTIX) has had a month that shareholders would love to forget; after hitting highs of $4.93 in the first few days of January the...
Cellceutix Corp (OTCMKTS:CTIX) is moving steadily higher in recent trading on accelerating volume. The stock recently topped out at $4.93 and has been consolidating since in...
Cellceutix Corp (OTCMKTS:CTIX) has had an incredible year running off $1.50 to recent highs of $4.93. Currently in consolidation mode CTIX continues to be one of...
Cellceutix Corp (OTCMKTS:CTIX) is making a spectacular move up after the FDA grants Qualified Infectious Disease Product (QIDP) status to Brilacidin for the treatment of Acute...
